MorphImmune
MorphImmune is a preclinical biotechnology company developing small-molecule therapeutics, headquartered in West Lafayette, Indiana. Founded in 2020, the privately held firm has raised approximately $32 million to fund early-stage drug discovery.
- Company typePrivate
- Founded2020
- HeadquartersWest Lafayette, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
MorphImmune firmographics
Firmographics- Name
- MorphImmune
- Legal name
- MorphImmune Inc.
- Website
- https://morphimmune.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MorphImmune is a preclinical biotechnology company developing small-molecule therapeutics, headquartered in West Lafayette, Indiana. Founded in 2020, the privately held firm has raised approximately $32 million to fund early-stage drug discovery.
- Ownership category
- akta.pro rank
MorphImmune industry classification
Industry- Product category
- Preclinical Targeted Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
Keywords
Where MorphImmune is headquartered
LocationHeadquarters
- HQ city
- West Lafayette
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MorphImmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
MorphImmune product offering
Product offeringCore offering
MorphImmune is a preclinical biotechnology company developing small-molecule therapeutics, with a focus on targeted therapies. The company is conducting early-stage drug discovery research aimed at producing novel molecular therapeutics, primarily in oncology, intended to be advanced through licensing or partnership with larger pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical small-molecule therapeutics pipeline
Companies that use MorphImmune
Customer profileIdeal customer profiles1 record
MorphImmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MorphImmune partnerships and signals
Strategic signalScale indicators2 records
MorphImmune competitors and assessment
Company assessmentDirect peers
- Morphic Holding: Morphic Holding developed oral small-molecule integrin inhibitors and was acquired by Eli Lilly in 2024; comparable as a clinical-stage small-molecule immunology company with an academic-founder origin story similar to MorphImmune.
- Arvinas: Arvinas develops small-molecule therapeutics, including targeted protein degraders; directly comparable as a small-molecule biotech pursuing novel mechanism-driven drug discovery.
- Black Diamond Therapeutics: Black Diamond is a precision oncology company developing small-molecule masterkey therapies against oncogenic mutations; comparable as a discovery-stage small-molecule biotech with academic roots.
- Theseus Pharmaceuticals: Theseus developed small-molecule kinase inhibitors to overcome resistance mutations; comparable as a small-molecule targeted therapeutics biotech in oncology/immune-related indications.
- Mirati Therapeutics: Mirati Therapeutics developed targeted small-molecule oncology drugs and was acquired by Bristol-Myers Squibb in 2024; comparable as a clinical-stage targeted small-molecule biotech.
- Revolution Medicines: Revolution Medicines develops targeted small-molecule inhibitors, including RAS(ON) inhibitors, and represents another academic-rooted small-molecule biotech that scaled from preclinical to clinical.
Broad incumbents
- Incyte Corporation: Incyte is a larger biopharma with a portfolio spanning small-molecule JAK inhibitors and immunology drugs; relevant as an established incumbent in the same targeted small-molecule immunology space MorphImmune is pursuing.
- Bristol-Myers Squibb: BMS is a large pharma with deep small-molecule immunology and oncology franchises (e.g., kinase inhibitors, checkpoint modulators); represents both a potential acquirer and the broader competitive landscape for small-molecule therapeutics.
- Pfizer: Pfizer operates a broad small-molecule discovery and development engine across multiple therapeutic areas; relevant as an incumbent acquirer and benchmark for pipeline scale in targeted therapeutics.
Emerging players
- Lycia Therapeutics: Lycia is an emerging biotech developing small-molecule degraders of extracellular and membrane proteins; comparable as an emerging small-molecule discovery platform targeting immune and disease-relevant pathways.
Market position
Customer concentration
MorphImmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
MorphImmune leadership team
Management profileNumber of profiles
Profiles3 records
MorphImmune funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MorphImmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MorphImmune
What does MorphImmune do?
MorphImmune is a preclinical biotechnology company developing small-molecule therapeutics, with a focus on targeted therapies. The company is conducting early-stage drug discovery research aimed at producing novel molecular therapeutics, primarily in oncology, intended to be advanced through licensing or partnership with larger pharmaceutical companies.
Is MorphImmune a public or private company?
MorphImmune is a private company. It is classified as venture growth investor backed and is currently operating.
When was MorphImmune founded?
MorphImmune was founded in 2020. It employs 1 to 10 people.
Where is MorphImmune based?
MorphImmune is headquartered in West Lafayette, United States, in the North America region.
Who are MorphImmune's main competitors?
Direct peers on record are Morphic Holding, Arvinas, Black Diamond Therapeutics, Theseus Pharmaceuticals, Mirati Therapeutics and Revolution Medicines. Broad incumbents are Incyte Corporation, Bristol-Myers Squibb and Pfizer. Lycia Therapeutics is listed as an emerging player.
Does MorphImmune have an API?
No public API is recorded for MorphImmune.
What industry is MorphImmune in?
MorphImmune's product category is Preclinical Targeted Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 541714 and its SIC code is 2834.